A substituted amino heterocyclic carboxamide compound as represent by formula (Φ), or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvent compound, a crystal form, a stereoisomer or an isotopic variant of the compound, and a pharmaceutical composition thereof, and the use thereof as an FLT3/AXL kinase inhibitor for treating acute myelocytic leukemia. ##STR00001##

The presently claimed invention is related to compositions and methods for treating H.sub.2S related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the H.sub.2S related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.

The presently claimed invention is related to compositions and methods for treating H.sub.2S related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the H.sub.2S related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.

Provided, inter alia, are methods and compositions for treating FTO-mediated cancer.

Provided, inter alia, are methods and compositions for treating FTO-mediated cancer.

An aromatic heterocyclic compound having a tricyclic structure and a preparation method therefor and application thereof, and in particular, a compound as shown in formula I, or an optical isomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The compound shown in formula I may be used to treat diseases associated with a PD-1/PD-L1 signaling pathway.

An aromatic heterocyclic compound having a tricyclic structure and a preparation method therefor and application thereof, and in particular, a compound as shown in formula I, or an optical isomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The compound shown in formula I may be used to treat diseases associated with a PD-1/PD-L1 signaling pathway.

The present disclosure is directed to the treatment of Alzheimer's disease by administering 1′,3′-dihydro-2H-spiro[imidazo[1,2α]pyridine-3,2′-inden]-2-one orally at a daily dose of 180 mg as a single active agent or co-administered with donepezil hydrochloride and/or memantine hydrochloride.

The present disclosure is directed to the treatment of Alzheimer's disease by administering 1′,3′-dihydro-2H-spiro[imidazo[1,2α]pyridine-3,2′-inden]-2-one orally at a daily dose of 180 mg as a single active agent or co-administered with donepezil hydrochloride and/or memantine hydrochloride.

PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.